ReviewDrugs2020
Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs.
Review in Drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Pooled it
- Coenzyme Q10 as a potential add-on treatment for patients suffering from painful diabetic neuropathy: results of a placebo-controlled randomized trial.European journal of clinical pharmacology · 2022Trial
- Trial
- Real world treatment patterns among patients with painful diabetic peripheral neuropathy in the United States.Pain medicine (Malden, Mass.) · 2026Article
- Real-World Safety and Effectiveness of Mirogabalin in Chinese Adults with Diabetic Peripheral Neuropathic Pain: a Protocol of ReMIssion Study.Pain and therapy · 2026Article
- Preservation of Nociceptor Intraepidermal Nerve Fibres in Diabetic Neuropathic Pain.Journal of diabetes research · 2026Article
- Calcium Channel αPain and therapy · 2025Review
- A Pragmatic Approach to Improving Management and Patient Flow for Painful Diabetic Neuropathy in UK Primary Care.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Complementary Therapies of Diabetic Peripheral Neuropathy and Intermittent Claudication.Healthcare (Basel, Switzerland) · 2025Article
- Network Meta-analysis of Randomized Controlled Trials Assessing Neuromodulation Therapies for Painful Diabetic Neuropathy.Neurology and therapy · 2025Article
- Diabetic neuropathy: cutting-edge research and future directions.Signal transduction and targeted therapy · 2025Review
- Can Spinal Cord Stimulation be Considered as a Frontier for Chronic Pain in Diabetic Foot?Pain and therapy · 2025Review
- Exploring the Therapeutic Potential of Natural Plants in Modulating Molecular and Cellular Pathways Involved in Diabetic Neuropathy: Mechanism and Biochemical Evaluation.Current pharmaceutical design · 2025Review
- A Conceptual Model of Patient Experiences of Painful Diabetic Peripheral Neuropathy to Support Clinical Outcomes Assessment.Journal of pain research · 2025Article
- Review of nonpharmacological interventions for delaying the effects of cerebral neuropathy caused by diabetes.Frontiers in endocrinology · 2025Review
- Perspectives on Stem Cell Therapy in Diabetic Neuropathic Pain.Neurology international · 2024Review
- Novel drugs affecting diabetic peripheral neuropathy.Iranian journal of basic medical sciences · 2024Review
- Effect of Carnosine Supplementation as Add-On Therapy With Vitamin B Complex in People With Type 2 Diabetes and Diabetic Neuropathy: A Randomized Controlled Study.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Research Progress of Coenzyme Q in Diabetes Mellitus and Its Common Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a high prevalence of painful diabetic polyneuropathy (pDPN) with around one-third of all patients with diabetes suffering from pDPN. pDPN has debilitating consequences, with a major impact on morbidity and quality of life. Unfortunately, there is no globally licenced pharmacotherapy that modulates the underlying disease mechanisms to prevent or halt the progression of diabetic neuropathy. The cornerstone of treatment therefore remains optimising glycaemic control and cardiovascular risk factors, and symptom control. Evidence from placebo-controlled studies has shown that antidepressants and anticonvulsants are effective for alleviating pDPN. Current clinical guidelines recommend the treatment of pDPN through the use of amitriptyline (tricyclic antidepressant), duloxetine (serotonin norepinephrine reuptake inhibitor), gabapentin and pregabalin (α2-δ ligands), tramadol and tapentadol (μ receptor agonists and norepinephrine reuptake inhibitors) and topical agents such as capsaicin (transient receptor potential V1 receptor desensitizer), although the latter is known to cause degeneration of small nerve fibers. pDPN can be difficult to treat, which frustrates healthcare providers, patients and caregivers. There is an additional need for clinical trials of novel therapeutic agents and optimal combinations for the management of pDPN. This article reviews the pharmacological management of pDPN, emerging therapies, the difficulties of placebo response in clinical trials and novel proposed biomarkers of treatment response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.